Preclinical safety study of a recombinant Streptococcus pyogenes vaccine formulated with aluminum adjuvant

Harm HogenEsch, Anisa Dunham, Elodie Burlet, Fangjia Lu, Yung Yi C Mosley, Garry Morefield

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A recombinant vaccine composed of a fusion protein formulated with aluminum hydroxide adjuvant is under development for protection against diseases caused by Streptococcus pyogenes. The safety and local reactogenicity of the vaccine was assessed by a comprehensive series of clinical, pathologic and immunologic tests in preclinical experiments. Outbred mice received three intramuscular injections of 1/5th of the human dose (0.1 ml) and rabbits received two injections of the full human dose. Control groups received adjuvant or protein antigen. The vaccine did not cause clinical evidence of systemic toxicity in mice or rabbits. There was a transient increase of peripheral blood neutrophils after the third vaccination of mice. In addition, the concentration of acute phase proteins serum amyloid A and haptoglobin was significantly increased 1 day after injection of the vaccine in mice. There was mild transient swelling and erythema of the injection site in both mice and rabbits. Treatment-related pathology was limited to inflammation at the injection site and accumulation of adjuvant-containing macrophages in the draining lymph nodes. In conclusion, the absence of clinical toxicity in two animal species suggest that the vaccine is safe for use in a phase I human clinical trial.

Original languageEnglish (US)
Pages (from-to)222-230
Number of pages9
JournalJournal of Applied Toxicology
Volume37
Issue number2
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

Streptococcus pyogenes
Aluminum
Vaccines
Safety
Injections
Toxicity
Rabbits
Aluminum Hydroxide
Serum Amyloid A Protein
Synthetic Vaccines
Haptoglobins
Acute-Phase Proteins
Macrophages
Pathology
Immunologic Tests
Clinical Trials, Phase I
Intramuscular Injections
Swelling
Erythema
Animals

Keywords

  • acute phase proteins
  • injection site
  • lymph nodes
  • preclinical safety
  • Streptococcus pyogenes
  • vaccine

ASJC Scopus subject areas

  • Toxicology

Cite this

Preclinical safety study of a recombinant Streptococcus pyogenes vaccine formulated with aluminum adjuvant. / HogenEsch, Harm; Dunham, Anisa; Burlet, Elodie; Lu, Fangjia; Mosley, Yung Yi C; Morefield, Garry.

In: Journal of Applied Toxicology, Vol. 37, No. 2, 01.02.2017, p. 222-230.

Research output: Contribution to journalArticle

HogenEsch, Harm ; Dunham, Anisa ; Burlet, Elodie ; Lu, Fangjia ; Mosley, Yung Yi C ; Morefield, Garry. / Preclinical safety study of a recombinant Streptococcus pyogenes vaccine formulated with aluminum adjuvant. In: Journal of Applied Toxicology. 2017 ; Vol. 37, No. 2. pp. 222-230.
@article{3477481d66854ec9ab4df931960c4f6c,
title = "Preclinical safety study of a recombinant Streptococcus pyogenes vaccine formulated with aluminum adjuvant",
abstract = "A recombinant vaccine composed of a fusion protein formulated with aluminum hydroxide adjuvant is under development for protection against diseases caused by Streptococcus pyogenes. The safety and local reactogenicity of the vaccine was assessed by a comprehensive series of clinical, pathologic and immunologic tests in preclinical experiments. Outbred mice received three intramuscular injections of 1/5th of the human dose (0.1 ml) and rabbits received two injections of the full human dose. Control groups received adjuvant or protein antigen. The vaccine did not cause clinical evidence of systemic toxicity in mice or rabbits. There was a transient increase of peripheral blood neutrophils after the third vaccination of mice. In addition, the concentration of acute phase proteins serum amyloid A and haptoglobin was significantly increased 1 day after injection of the vaccine in mice. There was mild transient swelling and erythema of the injection site in both mice and rabbits. Treatment-related pathology was limited to inflammation at the injection site and accumulation of adjuvant-containing macrophages in the draining lymph nodes. In conclusion, the absence of clinical toxicity in two animal species suggest that the vaccine is safe for use in a phase I human clinical trial.",
keywords = "acute phase proteins, injection site, lymph nodes, preclinical safety, Streptococcus pyogenes, vaccine",
author = "Harm HogenEsch and Anisa Dunham and Elodie Burlet and Fangjia Lu and Mosley, {Yung Yi C} and Garry Morefield",
year = "2017",
month = "2",
day = "1",
doi = "10.1002/jat.3349",
language = "English (US)",
volume = "37",
pages = "222--230",
journal = "Journal of Applied Toxicology",
issn = "0260-437X",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Preclinical safety study of a recombinant Streptococcus pyogenes vaccine formulated with aluminum adjuvant

AU - HogenEsch, Harm

AU - Dunham, Anisa

AU - Burlet, Elodie

AU - Lu, Fangjia

AU - Mosley, Yung Yi C

AU - Morefield, Garry

PY - 2017/2/1

Y1 - 2017/2/1

N2 - A recombinant vaccine composed of a fusion protein formulated with aluminum hydroxide adjuvant is under development for protection against diseases caused by Streptococcus pyogenes. The safety and local reactogenicity of the vaccine was assessed by a comprehensive series of clinical, pathologic and immunologic tests in preclinical experiments. Outbred mice received three intramuscular injections of 1/5th of the human dose (0.1 ml) and rabbits received two injections of the full human dose. Control groups received adjuvant or protein antigen. The vaccine did not cause clinical evidence of systemic toxicity in mice or rabbits. There was a transient increase of peripheral blood neutrophils after the third vaccination of mice. In addition, the concentration of acute phase proteins serum amyloid A and haptoglobin was significantly increased 1 day after injection of the vaccine in mice. There was mild transient swelling and erythema of the injection site in both mice and rabbits. Treatment-related pathology was limited to inflammation at the injection site and accumulation of adjuvant-containing macrophages in the draining lymph nodes. In conclusion, the absence of clinical toxicity in two animal species suggest that the vaccine is safe for use in a phase I human clinical trial.

AB - A recombinant vaccine composed of a fusion protein formulated with aluminum hydroxide adjuvant is under development for protection against diseases caused by Streptococcus pyogenes. The safety and local reactogenicity of the vaccine was assessed by a comprehensive series of clinical, pathologic and immunologic tests in preclinical experiments. Outbred mice received three intramuscular injections of 1/5th of the human dose (0.1 ml) and rabbits received two injections of the full human dose. Control groups received adjuvant or protein antigen. The vaccine did not cause clinical evidence of systemic toxicity in mice or rabbits. There was a transient increase of peripheral blood neutrophils after the third vaccination of mice. In addition, the concentration of acute phase proteins serum amyloid A and haptoglobin was significantly increased 1 day after injection of the vaccine in mice. There was mild transient swelling and erythema of the injection site in both mice and rabbits. Treatment-related pathology was limited to inflammation at the injection site and accumulation of adjuvant-containing macrophages in the draining lymph nodes. In conclusion, the absence of clinical toxicity in two animal species suggest that the vaccine is safe for use in a phase I human clinical trial.

KW - acute phase proteins

KW - injection site

KW - lymph nodes

KW - preclinical safety

KW - Streptococcus pyogenes

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=84971510385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971510385&partnerID=8YFLogxK

U2 - 10.1002/jat.3349

DO - 10.1002/jat.3349

M3 - Article

C2 - 27241723

AN - SCOPUS:84971510385

VL - 37

SP - 222

EP - 230

JO - Journal of Applied Toxicology

JF - Journal of Applied Toxicology

SN - 0260-437X

IS - 2

ER -